VectorY to Present a Poster at the European Network to Cure ALS (ENCALS) Annual Meeting

VectorY to Present a Poster at the European Network to Cure ALS (ENCALS) Annual Meeting

May 26, 2022 by Business Wire Health News

Key Facts

  • AMSTERDAM--(BUSINESS WIRE)--VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of muscular and neurodegenerative disorders through vectorized antibodies, today announces presentation of a poster at the European Network to Cure ALS (ENCALS) Annual Meeting at the University of Edinburgh on 1-3 June, 2022.
  • Members of the VectorY team will attend the conference in person and will be available to discuss the poster.
  • ENDS Notes to Editors About VectorY VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for neurodegenerative and -muscular diseases with high unmet medical need.
  • Founded in October 2020 and based in the Amsterdam Science Park, VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics based on a novel AAV gene therapy platform, antibody-based targeted protein degradation technologies and proprietary manufacturing technology.

Click To Read Full Article

INFRASTRUCTURE
PERSON
EVENT
GEOGRAPHY
MISCELLANEOUS

This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.

Was this content valuable for you?